Market Quick Take - April 17, 2020

Macro 3 minutes to read

Steen Jakobsen

Chief Investment Officer

Summary:  The late market rally has extended further overnight in the wake of the US President Trump plan for phased reopening of the US economy, but even more so in late hours on reports that a drug from Gilead has been proving successful in treating Covid19 patients. We look forward to an interesting session ahead of the weekend, particularly for gold prices, as the recent gold narrative has come under pressure.


The market continues to look through terrible data, including yesterday’s US jobless claims and weak Chinese GDP and Retail Sales data, and is trading at new local highs on anticipation of economies reopening and hopes that a new drug treatment will help lift longer term uncertainty about the Covid19 pandemic.

What is our trading focus?

  • XAUUSD (spot Gold) – the latest sentiment drift to the positive side and narrative that a plan to return to normal is now afoot are seeing spot gold trading back through 1700 technical support. This will be a key test of sentiment given the amount of buying that occurred following the latest Fed bailout. Support at $1680 and $1650.
  • US500.I (US S&P500 Index) – the action in the big tech stocks was unrelenting recently, with the broader market participating less enthusiastically in the recent rally. But overnight, the S&P 500 futures have outperformed the tech-heavy Nasdaq 100 by a solid margin as we watch whether this rally in stocks broadens. The next key US S&P 500 level is around 2930, the 61.8% retracement of the entire sell-off wave.
  • USDCAD – in FX, the USD remains negatively correlated with risk appetite and the USDCAD pair is an interesting to watch whether this latest surge in hope over the progress of reopening and Covid19 treatment can fully reverse can send he pair back toward the recent lows around 1.3855. CAD also captures any strength or weakness in forward crude oil prices, a key sign of whether the market sees production cuts reining in further downside risk.
  • Gilead Sciences (GILD:xnas) – this stock will receive intense focus today after a report from a medical news publication Stat cited a video made by an infectious disease researcher at the University of Chicago who reported that patients (apparently a selection of 125 with severe Covid19 symptoms) being treated with Gilead’s Remdesivir were “seeing rapid recoveries in fever and respiratory symptoms”, with most patients discharged and only two patients dying - shares rose 10% in extended trading yesterday on the news. It has been highlighted that the news hit the wire just after the close when liquidity was thin, and that the author on Stat has before been part of investigations around exaggerated news. A lot of call option activity with strike $80 and short expiry happened just before the release. Studies from China never found anything conclusive on Remdesivir so we encourage clients to hesitate putting too much weight on this event.
  • Schlumberger (SLB:xnys) – first US energy related company (services) to report Q1 earnings with everyone curious about the outlook from an oil services company on the ground. Consensus is looking for revenue to decline 4% y/y and EPS to decline by 19% y/y. With a 12-month trailing dividend yield of 15% it’s almost a given that the company will cut dividends, but the main question is by how much?

What is going on?

French President Macron sends a loud signal on the EU: In an interview with the FT, Macron loudly criticized the position of the economically stronger EU countries’ response to the Covid19 crisis and demanded that the EU do better. This is an important political signal as we ponder whether the EU is slipping into a new existential crisis:

For Mr Macron, the richer EU members have a special responsibility in the way they deal with this crisis. “We are at a moment of truth, which is to decide whether the European Union is a political project or just a market project. I think it’s a political project . . . We need financial transfers and solidarity, if only so that Europe holds on,” he says.

Covid19: US President Trump unveiled a three phase plan for reopening the US economy that local authorities could employ depending on the severity of local outbreaks of the Covid19 pandemic. Trump claimed as many as 29 states may be ready for Phase 1 within the week, which still only allows gatherings of 10 people or fewer and leaves schools closed. A downward trajectory in cases must be documented for two weeks before starting reopening.

Successful new Covid19 treatment? A report that some Chicago patients were showing rapid recovery from Covid19 symptoms after treatment with a Gilead Sciences drug emerged late yesterday and may have driven the large further rise in equities futures into this morning.

US Minneapolis Fed president Kashkari wrote an op-ed telling banks that suspending dividends and raising equity is the appropriate course of action here. In a day of strong gains for the market, this spooked financial stocks, particularly banks, where share prices dropped across the board.

The latest weekly US jobless claims report showed 5.2 million workers applied for claims for the first time, taking the total beyond 22 million for the past four weeks and estimates circulated that the US April unemployment rate could spike to as high as 20%.

Chinese economy shrank in Q1: China reported a Q1 GDP of -6.8% year-on-year, worse than the -6.0% expected. China’s March Industrial Production was reported down -1.1% year-on-year and Mar. Retail Sales at -15.8%.

 


What we are watching next?

Gold prices – stocks rallying is one thing, but the massive official response in cutting rates and bringing unprecedented policy support to the economy has seen gold only easing off the highs here. Gold price movements in the coming sessions help tell us whether the macro narrative is really buying into the outlook for normalization, with the first test around 1700 in spot gold now unfolding.

Stock market strength broadening or not?  As we discuss above with the strong S&P500 comeback overnight, the broader market has not shown enthusiastic participation in this rally, a situation that needs to change if the rally is to appear more healthy. A bit of extra focus on the worst hit industries as well might be merited today and earlier next week – names like Disney (DIS:xnys), Boeing (BA:xnys) and Marriott Hotels (MAR:xnys), for example.

Natural gas continues to find buyers below $1.60. It bounced strongly on Thursday despite a bigger-than-expected weekly inventory build. The combination of colder-than-normal end of April weather combined with ongoing shut-ins of shale oil wells adding support. Especially the latter need to be watch for signs of bottoming natural gas market.

Economic Calendar (times GMT)

  • 1300 – US St. Louis Fed President Bullard to speak at “Reinventing Bretton Woods Committee Seminar”– this won’t be a market mover, but any signals from the Fed on how it views the dysfunction of the USD as global currency and in effect, how it forces the Fed to act as the world’s bank is interesting. This crisis has laid bare once again that the USD as global money system doesn’t work.

Follow SaxoStrats on the daily Saxo Markets Call on your favorite podcast app:

Apple Sportify Soundcloud Stitcher

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

Saxo Capital Markets HK is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo Capital Markets HK Limited holds a Type 1 Regulated Activity (Dealing in securities); Type 2 Regulated Activity (Dealing in Futures Contract) and Type 3 Regulated Activity (Leveraged foreign exchange trading) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong

By clicking on certain links on this site, you are aware and agree to leave the website of Saxo Capital Markets, proceed on to the linked site managed by Saxo Group and where you will be subject to the terms of that linked site.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

Please note that the information on this site and any product and services we offer are not targeted at investors residing in the United States and Japan, and are not intended for distribution to, or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. Please click here to view our full disclaimer.